Title: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Authors: Davies, Christina ×
Pan, Hongchao
Godwin, Jon
Gray, Richard
Arriagada, Rodrigo
Raina, Vinod
Abraham, Mirta
Medeiros Alencar, Victor Hugo
Badran, Atef
Bonfill, Xavier
Bradbury, Joan
Clarke, Michael
Collins, Rory
Davis, Susan R
Delmestri, Antonella
Forbes, John F
Haddad, Peiman
Hou, Ming-Feng
Inbar, Moshe
Khaled, Hussein
Kielanowska, Joanna
Kwan, Wing-Hong
Mathew, Beela S
Mittra, Indraneel
Müller, Bettina
Nicolucci, Antonio
Peralta, Octavio
Pernas, Fany
Petruzelka, Lubos
Pienkowski, Tadeusz
Radhika, Ramachandran
Rajan, Balakrishnan
Rubach, Maryna T
Tort, Sera
Urrútia, Gerard
Valentini, Miriam
Wang, Yaochen
Peto, Richard #
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group #
Contributors: Neven, Patrick
Issue Date: 9-Mar-2013
Publisher: The Lancet Publishing Group
Series Title: The Lancet vol:381 issue:9869 pages:805-16
Abstract: For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.
ISSN: 0140-6736
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science